Abstract
Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in systemic lupus erythematosus (SLE) using single-cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from 2 new-onset SLE patients and 1 healthy control, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (SLE vs HC primary, plus B cell, T cell, monocyte, ISG-high, and pro-SLE cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE162577 (10,756 cells after quality filtering) identified 417 NOVEL_ALL priority candidates — the highest NOVEL_ALL rate (77%) across the inventor's series of scRNA-seq drug repurposing analyses. Top candidates: Dichlorodiamine-Platinum (priority 202,502), MRE-269 (prostacyclin agonist, 159,481), Crenolanib (FLT3/PDGFR inhibitor, 127,564), EPZ-5676 (DOT1L inhibitor, 110,960), Nilutamide (AR antagonist, 113,195), KPT-330/selinexor (XPO1 inhibitor, 24,415). Crenolanib implicates plasmacytoid DC FLT3 signaling as a novel SLE therapeutic target; EPZ-5676 implicates H3K79 methylation in ISG regulation; KPT-330 achieves NOVEL_ALL status for the fourth consecutive pipeline. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.